MF59

From Wikipedia, the free encyclopedia

MF59 is an immunologic adjuvant that uses squalene. It is Novartis' proprietary adjuvant that is added to influenza vaccines to help stimulate the human body's immune response through production of CD4 memory cells.

MF59 is the first oil-in-water influenza vaccine adjuvant to be commercialized in combination with a seasonal influenza virus vaccine. MF59 is used as an adjuvant in Europe whereas; in the United States Alum (aluminum hydroxide) is used.

It was developed in the 1990s by researchers at Ciba-Geigy, a Novartis heritage company, and Chiron, acquired by Novartis in 2006.[1]

See also

  • AS03, another squalene based adjuvant

References

  1. ↑ MF59 Adjuvant Fact Sheet, Novartis, June 2009.


This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.